Bio-Techne Corporation (TECH)
NASDAQ: TECH · Real-Time Price · USD
44.43
+1.13 (2.61%)
May 18, 2026, 4:00 PM EDT - Market closed
Bio-Techne Revenue
Bio-Techne had revenue of $311.42M in the quarter ending March 31, 2026, a decrease of -1.51%. This brings the company's revenue in the last twelve months to $1.21B, up 0.17% year-over-year. In the fiscal year ending June 30, 2025, Bio-Techne had annual revenue of $1.22B with 5.23% growth.
Revenue (ttm)
$1.21B
Revenue Growth
+0.17%
P/S Ratio
5.75
Revenue / Employee
$390,584
Employees
3,100
Market Cap
6.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.22B | 60.58M | 5.23% |
| Jun 30, 2024 | 1.16B | 22.36M | 1.97% |
| Jun 30, 2023 | 1.14B | 31.10M | 2.81% |
| Jun 30, 2022 | 1.11B | 174.57M | 18.75% |
| Jun 30, 2021 | 931.03M | 192.34M | 26.04% |
| Jun 30, 2020 | 738.69M | 24.69M | 3.46% |
| Jun 30, 2019 | 714.01M | 71.01M | 11.04% |
| Jun 30, 2018 | 642.99M | 79.99M | 14.21% |
| Jun 30, 2017 | 563.00M | 63.98M | 12.82% |
| Jun 30, 2016 | 499.02M | 46.78M | 10.34% |
| Jun 30, 2015 | 452.25M | 94.48M | 26.41% |
| Jun 30, 2014 | 357.76M | 47.19M | 15.19% |
| Jun 30, 2013 | 310.58M | -3.99M | -1.27% |
| Jun 30, 2012 | 314.56M | 24.60M | 8.48% |
| Jun 30, 2011 | 289.96M | 20.92M | 7.77% |
| Jun 30, 2010 | 269.05M | 5.09M | 1.93% |
| Jun 30, 2009 | 263.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Corcept Therapeutics | 769.10M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Centessa Pharmaceuticals | 15.00M |
TECH News
- 4 days ago - Bio-Techne resumed with an Outperform at RBC Capital - TheFly
- 6 days ago - Bio-Techne Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Bio-Techne price target lowered to $66 from $75 at Deutsche Bank - TheFly
- 11 days ago - Bio-Techne price target lowered to $49 from $70 at Baird - TheFly
- 11 days ago - Bio-Techne price target lowered to $50 from $65 at Stifel - TheFly
- 11 days ago - Bio-Techne price target lowered to $50 from $54 at Evercore ISI - TheFly
- 11 days ago - Bio-Techne price target lowered to $70 from $80 at Citi - TheFly
- 11 days ago - Bio-Techne price target lowered to $62 from $76 at Wells Fargo - TheFly